• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human E3 ubiquitin-protein ligase Praja-1 (PJA1)

ACP13642

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP13642 Target NamePJA1
Target SynonymsE3 ubiquitin-protein ligase Praja 1; E3 ubiquitin-protein ligase Praja-1; PJA1; PJA1_HUMAN; PRAJA 1; Praja ring finger 1; Praja1; RING finger protein 70; RNF 70; RP23-414J22.4FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-643
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8NG27
Background Information
  • Uniprot Id

    Q8NG27

  • Target Species

    Human

  • Target Name

    PJA1

  • Target Full Name

    E3 ubiquitin-protein ligase Praja-1

  • Target Function

    Has E2-dependent E3 ubiquitin-protein ligase activity. Ubiquitinates MAGED1 antigen leading to its subsequent degradation by proteasome. May be involved in protein sorting.

  • Target Tissue Specificity

    Expressed in various regions of the brain including the cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe and putamen. Highest levels in the cerebral cortex.

  • Target Synonyms

    E3 ubiquitin-protein ligase Praja 1; E3 ubiquitin-protein ligase Praja-1; PJA1; PJA1_HUMAN; PRAJA 1; Praja ring finger 1; Praja1; RING finger protein 70; RNF 70; RP23-414J22.4

Inquire Recombinant Human E3 ubiquitin-protein ligase Praja-1 (PJA1) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification